Company launches clinical study of AI-designed oral formulation following MHRA approval, marking a major milestone in AI-driven drug development.
Our Global Capability Center (GCC) in Bengaluru drives our major software development initiatives. Complementing this, our Bengaluru facility manufactures antibodies for research and diagnostics. Through these integrated technology and biotech operations, we are proud to contribute to India’s growth story in the life sciences sector.
Biologics manufacturing veteran brings over two decades of expertise in biosimilars, GMP operations, and large-scale biopharmaceutical manufacturing
Eris Lifesciences posts sharp profit surge in FY26 driven by strong diabetes portfolio growth
Dr. Upadhyay brings over 25 years of global leadership experience across life sciences, regulated manufacturing, diagnostics, and research-led environments
Company’s FY26 EBITDA rses 20% to Rs. 8,475 crore; Net profit grows 15% amid strong operational performance
The company reported free cash flow of Rs. 2,590 Mn for FY26
The state has received Rs. 84,000 crore investments in the sector over two years, positioning Hyderabad among the world’s leading life sciences clusters
The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies
Subscribe To Our Newsletter & Stay Updated
